title: Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the dog: effect of pargyline pretreatment.
abstract: Adult beagle dogs of either sex were injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-HCl (2.5 mg/kg, i.v.) alone or after pretreatment with pargyline (5.0 mg/kg, s.c., twice), with pargyline alone, or were uninjected. Groups were killed 2 h, 3 weeks, or 3 months after injection, and several brain areas were assayed for biogenic amines and their synthetic and degradative enzymes. MPTP caused a massive and permanent loss of striatal dopamine, tyrosine hydroxylase, and 3,4-dihydroxyphenylalanine decarboxylase activities and the loss of cells within the substantia nigra pars compacta. Dopamine and norepinephrine also were depleted to various degrees in cortex, olfactory bulb, and hypothalamus; however, dopamine beta-hydroxylase activity in cortex was normal. There was no cell loss in the ventral tegmental area or locus ceruleus. The activities of monoamine oxidase (MAO)-A and MAO-B in cortex and caudate were not affected by MPTP. Despite a permanent loss of the nigrostriatal system, the dogs exhibited only a transient hypokinesia lasting 1-2 weeks. Pargyline pretreatment prevented the loss of striatal dopamine and cells from the substantia nigra, but did not prevent a prolonged but reversible decrease in the concentration of dopamine metabolites. It is argued that this apparent inhibition of MAO is due not to suicide inactivation of the enzyme by MPTP, but to reversible inhibition by accumulation of the pyridinium metabolite, 1-methyl-4-phenylpyridinium, selectivity in aminergic terminals.
authors.affiliation: Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20892.
authors.forename: J N
authors.initials: JN
authors.lastname: Johannessen
authors.forename: C C
authors.initials: CC
authors.lastname: Chiueh
authors.forename: J P
authors.initials: JP
authors.lastname: Bacon
authors.forename: N A
authors.initials: NA
authors.lastname: Garrick
authors.forename: R S
authors.initials: RS
authors.lastname: Burns
authors.forename: V K
authors.initials: VK
authors.lastname: Weise
authors.forename: I J
authors.initials: IJ
authors.lastname: Kopin
authors.forename: J E
authors.initials: JE
authors.lastname: Parisi
authors.forename: S P
authors.initials: SP
authors.lastname: Markey
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D005260:Female; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010293:Pargyline / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D014018:Tissue Distribution; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D011725:Pyridines; D015102:3,4-Dihydroxyphenylacetic Acid; D010293:Pargyline; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; D008995:Monoamine Oxidase; D004298:Dopamine; D009638:Norepinephrine